FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年3月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份（不包括庫 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年3月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 1,060,683,690 | 11,833,400 | | 1,072,517,090 | | 增加 / 減少 (-) | | | -11,564,325 | 11,697,900 | | | | 本月底結存 | | | 1,049,119,365 | 23 ...

医渡科技港股市值62.12亿港元，在医疗服务Ⅱ行业中排名第10。主要指标见下表： 2月27日，医渡科技(02158.HK)再度实施股份回购，当日以每股约5.99港元的价格回购32.2万股，总耗资 近200万港元。截至目前，公司年内已完成19次回购，累计斥资已超7600万港元，以连贯动作彰显对自 身长期价值与AI医疗行业前景的坚定信心。 截至2026年2月27日收盘，医渡科技(02158.HK)报收于5.97港元，上涨0.84%，成交量380.13万股，成交 额2274.38万港元。投行对该股的评级以跑赢行业(OUTPERFORM)为主，近90天内共有1家投行给出跑 赢行业(OUTPERFORM)评级，近90天的目标均价为6.8港元。中金公司最新一份研报给予医渡科技跑赢 行业(OUTPERFORM)评级，目标价6.8港元。 机构评级详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

2025 年医疗大模型品牌推荐 2025 年医疗大模型品牌推荐 海量知识深度整合，智能生成革新医疗范式 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 医疗大模型定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 3 | | 2.1 市场规模 | 3 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 3 | | 3.1 市场评估维度 | 3 | | 3.2 市场竞争格局 | 4 | | 3.3 十大品牌推荐 | 4 | | 四、发展趋势 | 5 | | 4.1 底层算法与数据质量升级 | 6 | | 4.2 应用形态与部署模式多元化 | 6 | | 4.3 商业模式与生态构建平台化 | 6 | 自 2019 年医疗大模型诞生以来，其发展经历了从通用模型的基础能力迁移，到专业医 疗知识的深度对齐，再到多模态与临床工作流融合的快速演进。早期模型如 BioBERT、ClinicalBERT 通过生物医学语料预训练夯实了基础能力；随后 Med-PaLM、 HuaTuoGPT 等模型通过指令微调与知识增强，在医学问答、报告生成等任务中展 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its ongoing share buyback program, having repurchased 322,000 shares at approximately HKD 5.99 per share, totaling nearly HKD 2 million on February 27 [1] Group 1: Share Buyback Activity - Yidu Tech has completed 19 share buybacks this year, with a total expenditure exceeding HKD 76 million [1] - The buyback actions are seen as a consistent strategy to reinforce the company's commitment to its value and the AI healthcare sector [1] Group 2: Industry Insights - According to a report by Zhonghang Securities, domestic and international healthcare companies are increasingly investing in AI products and services across various areas, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system "Yidu Zhixun" [1] - A project supported by Yidu Tech for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]

Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its recent share buyback activities, totaling over 76 million HKD this year [1] Group 1: Share Buyback Activities - On February 27, Yidu Tech repurchased 322,000 shares at approximately 5.99 HKD per share, with a total expenditure of nearly 2 million HKD [1] - The company has completed 19 buybacks this year, reflecting its commitment to enhancing shareholder value [1] Group 2: Industry Trends - A report from Zhonghang Securities highlights that domestic and international healthcare companies are increasingly investing in AI products and services across various sectors, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value penetrating various stages from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system, "Yidu Zhixun" [1] - The company's project for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]

医渡科技(02158)发布公告，于2026年2月27日，该公司斥资192.73万港元回购32.2万股股份，每股回购 价5.93-6港元。 ...

格隆汇2月27日丨医渡科技(02158.HK)公告，2月27日耗资192.7万港元回购32.2万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月27日，该公司斥资192.73万港元回购32.2万股 股份，每股回购价5.93-6港元。 ...